Impact of the AurkA Phe31-Ile polymorphism as a predictive marker on the succeptibility of HNSCC patients to Cetuximab therapy - Roth, A; Muth, J; Piontek, G; Buchberger, M; Wirth, M; Pickhard, A (Laryngo-Rhino-Otologie, 2019)